Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(60%)
Terminated
1(20%)

Phase Distribution

Ph phase_2
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Terminated(1)

Detailed Status

Recruiting2
Active, not recruiting1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

recruiting240%
active_not_recruiting120%
not_yet_recruiting120%
terminated120%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_2

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

NCT05733598
recruitingphase_2

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406
active_not_recruitingphase_1

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

NCT04336241
terminatedphase_2

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

NCT05733611
not_yet_recruitingphase_2

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

NCT07059611

Clinical Trials (5)

Showing 5 of 5 trials
NCT05733598Phase 2

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Recruiting
NCT06581406Phase 2

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Recruiting
NCT04336241Phase 1

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Active Not Recruiting
NCT05733611Phase 2

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Terminated
NCT07059611Phase 2

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5